REGENXBIO (NASDAQ:RGNX) Lowered to “Sell” Rating by StockNews.com

StockNews.com cut shares of REGENXBIO (NASDAQ:RGNX) from a hold rating to a sell rating in a research report released on Thursday morning.

RGNX has been the subject of several other reports. Raymond James reaffirmed an “outperform” rating and set a $18.00 price objective on shares of REGENXBIO in a research report on Thursday, October 10th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a report on Tuesday. Chardan Capital reissued a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a report on Wednesday, November 20th. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of REGENXBIO in a report on Wednesday, January 15th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a research note on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $34.82.

REGENXBIO Trading Up 1.3 %

Shares of RGNX stock opened at $7.95 on Thursday. The company has a market cap of $393.84 million, a P/E ratio of -1.58 and a beta of 1.28. The firm has a fifty day moving average price of $8.52 and a 200 day moving average price of $10.42. REGENXBIO has a 12 month low of $6.56 and a 12 month high of $28.80.

Institutional Trading of REGENXBIO

A number of hedge funds have recently added to or reduced their stakes in RGNX. GAMMA Investing LLC raised its stake in shares of REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 2,510 shares during the last quarter. FMR LLC raised its position in REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,656 shares during the last quarter. nVerses Capital LLC lifted its stake in shares of REGENXBIO by 183.3% in the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,200 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of REGENXBIO by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 3,720 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of REGENXBIO in the third quarter valued at about $140,000. 88.08% of the stock is owned by institutional investors and hedge funds.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.